Goldman Sachs Upgrades Genmab to Buy From Neutral, Adjusts Price Target to $30.50 From $24.50
22 april, 13:35
07:35 AM EDT, 04/22/2026 (MT Newswires) -- Genmab A/S (GMAB) has an average rating of buy and mean price target of $37.62, according to analysts polled by FactSet.
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
Ämnen i artikeln
Goldman Sachs Upgrades Genmab to Buy From Neutral, Adjusts Price Target to $30.50 From $24.50
22 april, 13:35
07:35 AM EDT, 04/22/2026 (MT Newswires) -- Genmab A/S (GMAB) has an average rating of buy and mean price target of $37.62, according to analysts polled by FactSet.
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
Ämnen i artikeln
Rapporter
Analys
Rapporter
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
